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The antiterminator Q gene of bacteriophage 933W
(Q933) was identified upstream of the stx2 gene in 90% of
human disease–origin Escherichia coli O157:H7 isolates
and in 44.5% of bovine isolates. Shiga toxin production was
higher in Q933-positive isolates than Q933-negative isolates.
This genetic marker may provide a useful molecular tool for
epidemiologic studies.
E
scherichia coli O157 is recognized worldwide as an
important cause of diarrheal disease, which in some
patients is followed by hemolytic uremic syndrome and
death (1). Aprimary virulence factor of this pathogen is the
prophage-encoded Shiga toxin (2). Greater Shiga toxin
production per bacterium is associated with increasing
severity of human disease (3,4). Because of its location in
the phage genome, the stx-gene variant dubbed stx2 is
under similar regulatory control as other phage late-genes,
as it is governed by the interaction of the transcription
antiterminator Q with the late promoter PR′ (5). 
Although cattle and other ruminants appear to be the
natural reservoir for E. coli O157 and other Shiga
toxin–producing E. coli (STEC), only a small fraction of
STEC serotypes routinely present in cattle are frequently
isolated from human patients. Mounting evidence suggests
that considerable genetic, phenotypic, and pathogenic
diversity exists among these pathogens (6–8).
Furthermore, genetic subtypes or lineages of E. coli O157
do not appear to be equally distributed among isolates of
bovine and human origin (7). The purpose of this study
was to examine the distribution of specific sequences
upstream of the stx2 gene among E. coli O157:H7 of
human and bovine origin, along with corresponding mag-
nitudes of Shiga toxin production. 
The Study
A total of 158 stx2-encoding E. coli O157:H7 isolates
were assayed, 91 isolates of bovine origin and 67 originally
isolated from ill persons (see online Appendixes 1 and 2;
http://www.cdc.gov/ncidod/EID/vol10no8/03-0784_
app1.htm and http://www.cdc.gov/ncidod/EID/vol10no8/
03-0784_app2.htm). All isolates demonstrated unique
banding patterns on pulsed-field gel electrophoresis
(PFGE). For polymerase chain reaction (PCR) analysis, 5
µL of DNA obtained from boiled stationary-phase bacteria
was added to a 50-µL PCR master mix containing a final
concentration of 1.5 (Q933) or 2.5 (Q21) mmol MgCl2, 200
µmol/L each deoxynucleoside triphosphate, 1 U Taq poly-
merase, 0.6 pg/µL of primer 595 (5′-CCGAAGAAAAAC-
CCAGTAACAG-3′) (9), and 0.6 pg/µL of either primer
Q933 (5′-CGGAGGGGATTGTTGAAGGC-3′;QStxf) (9) or
primer Q21 (5′-GAAATCCTCAATGCCTCGTTG-3′; this
study). PCR consisted of an initial denaturation at 94°C for
5 min; 30 cycles of 94°C for 30 s, 52°C (Q933) or 55°C (Q21)
for 1 min, and 72°C for 1 min; and a final 10-min extension
step at 72°C. E. coli strain 933 or FAHRP88 was used as a
positive control and master mix alone as a negative control.
All PCR products were separated by gel electrophoresis
(100 V) in 1% agarose gels, stained with ethidium bromide,
and visualized by using UV illumination. 
Shiga toxin production was determined by using a
commercially available enzyme-linked immunosorbent
assay (ELISA) kit (Premiere EHEC, Meridian
Diagnostics, Cincinnati, OH). Briefly, log-phase cells
from Luria-Bertani broth enrichments were diluted to 0.6
optical density (OD) at 600 nm, subsequently pelleted,
resuspended in phosphate-buffered saline, and induced by
exposure to UV light (240 nm) for 3 s (10). A 1:9 volume
of a 10x concentrate of brain heart infusion broth was
added to each culture and shaken at 37°C for 2.5 h.
Replicate cultures that were not exposed to UV light (non-
induced controls) were maintained at 4°C. Two hundred
microliters of each induced and noninduced enrichment
was subsequently used as the specimen in the EHEC
ELISA, as described (11). OD results were recorded for
each isolate both with and without UV induction. The rel-
ative change in Shiga toxin production after induction was
calculated for each isolate; (ODinduced)/ODnoninduced). E. coli
O157 (EDL933) and a toxin-negative control isolate were
assayed as positive and negative controls each time the
assay was repeated.
E. coli O157 isolates were classified on the basis of the
presence or absence of bands of the predicted size on the
Q933-595 and Q21-595 PCR reactions (Figure). A chi-
square test was used to determine whether different PCR
genotypes were equally distributed among isolates of
bovine and human origin. Likewise, a chi-square test was
used to assess the equality of distribution of PCR geno-
types among bovine isolates from different countries. One-
way analysis of variance for nonparametric data
(Kruskal-Wallis test) was used to identify differences in
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and induced E. coli O157 isolates as well as to determine
significant differences in the percent increase in toxin fol-
lowing induction. 
Previously, Kim et al. described a nonrandom distribu-
tion of E. coli O157 subtypes among cattle and humans by
using an octamer-based genome-scanning method (7). We
tested several of the isolates that had been previously char-
acterized. Nine had been previously identified as belonging
to the lineage I genotype and seven isolates as belonging to
the lineage II genotype. We found that all nine lineage I
isolates consistently amplified the Q933 target, regardless of
species of origin. All four bovine isolates classified as lin-
eage II by Kim et al. amplified the Q21 target. One lineage
II human isolate (NE015) amplified the Q933 target, and
another lineage II isolate (NE037) produced no amplicons
in either PCR reaction. One human isolate classified as lin-
eage II (ATCC 43889) amplified both target sequences,
presumably because of polylysogeny.
The distribution of the specific Q-gene alleles found
upstream of the prophage stx region among bovine isolates
may have a geographic component. The distribution of E.
coli O157 phage genotypes collected from healthy cattle
from diverse geographic areas is consistent with the vari-
able incidences of human disease in different countries
(Table 1). For example, six (75%) of eight Scottish bovine
isolates examined amplified the Q933 target, the same tar-
get that is frequently present in human isolates of human
disease origin. Scotland reports some of the highest inci-
dence rates of human E. coli O157–related diseases and
hemolytic uremic syndrome (13). In contrast, none of the
seven Australian E. coli O157 bovine isolates amplified
the 1750-bp fragment. Contrary to the situation in Scotland
and the United States, E. coli O157 infection of humans is
rarely reported in Australia (14). 
Conclusions
The Q933 gene target was more commonly identified in
human disease–associated strains of E. coli O157 than
from strains of bovine origin. Amplification of the Q933tar-
get, either alone or in combination with amplification of
the Q21 target from the same isolate, was identified in 60
(9%) of 66 (55/66 alone and 5/66 in combination with Q21;
1 isolate amplified neither target) compared to 40 (44%) of
91 (32/91 alone, and 8/91 in combination with Q21) of
bovine isolates (p < 0.001). Furthermore, these genetic
subtypes were nonrandomly distributed among the E. coli
O157 isolates of bovine origin obtained from different
countries (p < 0.05) (Table 1).
These limited data suggest that the distribution of E.
coli O157 strains in cattle may differ between countries or
regions, thereby providing an explanation for geographic
differences in the incidence of human E. coli O157 infec-
tion. More isolates from cattle need to be analyzed with
these methods to better characterize the E. coli O157 in the
bovine reservoir of each country.
Apositive reaction with the Q933 target was significant-
ly associated with higher OD results on the Shiga toxin
ELISA (both noninduced and induced) and higher-fold
increases in toxin production following induction than iso-
lates amplifying the Q21 target alone (p < 0.0001) (Table 2).
Despite these differences, we did not identify any clinical
associations between the magnitude of Shiga toxin produc-
tion and severity of human disease could be identified in
this study. Other, non–Shiga toxin–related virulence
factors and host susceptibility are also believed to play
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Figure. Ethidium bromide–stained gel of the amplification products
obtained from Q933-595 and Q21-595 polymerase chain reac-
tions. aEDL933, human isolate (ATCC43895). Obtained from the
STEC Center, Michigan State University. bFAHRP88, isolated from
Ohio dairy cow. cFAHRP39, human isolate (E29962) (12).
Table 1. Distribution of polymerase chain reaction results from bovine Escherichia coli  O157 isolates based on geographic origin
a   
Q allele 
Country of origin   No. tested  933  21  Both 
    N (%)  N (%)  N (%) 
USA  46  20 (44)  25 (54)  1 (2) 
Scotland  8  – (0)  2 (25)  6 (75) 
Australia  7  – (0)  7 (100)  – (0) 
Japan  17  3 (18)  14 (82)  – (0) 
Total  78  23 (29)  48 (62)  7 (9) 
a–, not detected. Percentages are read across rows, not down columns. Significant difference in proportion of  Q alleles isolated from different coun tries  
(p < 0.05, chi-square test for homogeneity).  essential roles in the outcome of clinical STEC infections.
The Q933-negative isolates obtained from human disease
might have lost this Q933-containing prophage by the time
of isolation, or these isolates might have been recovered
from patients also infected with STEC containing Q933-
type prophage (15). Whether specific Q-gene alleles
directly correlate with the magnitude of Shiga-toxin pro-
duction or whether other (unstudied) factors within the
phage lytic cascade genetically linked to specific Q alleles
instead are responsible for the magnitude of toxin produc-
tion is not known. 
The antiterminator Q, the protein product of the Q gene,
and PR′, the late promoter, are reputed to be involved in
regulating phage late-genes and, because of the location of
PR′ in prophage genome, of Shiga toxin production as well
(5). In E. coli O157 phage 933W (GenBank no. 9632466)
and E. coli O157 stx2vhd (GenBank no. 15718404), the 359-
bp sequence immediately upstream of the stx2 gene is near-
ly identical (>95% nucleotide identity). However, further
upstream of this area of identity, DNA sequences differ
significantly. In E. coli O157 933W, this gene is identified
as the antiterminator Q gene. In contrast, in E. coli O157
stx2vhd this area is occupied by a gene with >95% sequence
identity with the antiterminator Q gene of bacteriophage
21 (gi 4539472). The Q gene of bacteriophage 21 does not
share DNA sequence homology with the Q gene of bacte-
riophage 933W, and only 36% predicted amino acid
homology. Since the Q gene is reputed to play an impor-
tant role in regulating toxin production, our results provide
a plausible explanation (differential regulation of Shiga
toxin production) of why certain E. coli O157 genotypes
are more commonly isolated from human patients (7).
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